ANGO · Angiodynamics Inc · Investor Relations
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Upcoming events
| Date | Event | Type |
|---|---|---|
| 2026-10-08 12:00 UTC | AngioDynamics’ Fiscal 2027 First Quarter Financial Results | Results publication |
Recent news
| Date | Headline |
|---|---|
| 2026-10-02 |
AngioDynamics and The PERT Consortium® Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism Evidence
Investigator-Led Study Will Evaluate Imaging Biomarkers That May Help Predict Thrombectomy Success and Inform Long-Term PE Care LATHAM, N.Y. --(BUSINESS WIRE)--Oct. 2, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body’s |
| 2026-09-28 |
AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026
LATHAM, N.Y. --(BUSINESS WIRE)--Sep. 28, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report |
| 2026-07-28 |
AngioDynamics to Participate in Upcoming Investor Conferences
LATHAM, N.Y. --(BUSINESS WIRE)--Jul. 28, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today |
| 2026-07-14 |
AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability
Delivered its seventh consecutive quarter of double-digit Med Tech segment growth and positive adjusted EBITDA LATHAM, N.Y. --(BUSINESS WIRE)--Jul. 14, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the |
| 2026-06-30 |
AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026
LATHAM, N.Y. --(BUSINESS WIRE)--Jun. 30, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report |
| 2026-06-17 |
AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)
Prospective Feasibility Study to Examine IRE as a Tissue-Sparing, Minimally Invasive Option for Men with BPH-Related Lower Urinary Tract Symptoms LATHAM, N.Y. --(BUSINESS WIRE)--Jun. 17, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow |
| 2026-05-28 |
AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect
Palmetto GBA Medicare Coverage Effective July 5, 2026 Advances NanoKnife IRE Reimbursement Access in Prostate and Liver Cancer, Building on Category I CPT Codes Toward Broader National Payer Coverage LATHAM, N.Y. --(BUSINESS WIRE)--May 28, 2026-- AngioDynamics, Inc. |
| 2026-05-27 |
AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
LATHAM, N.Y. --(BUSINESS WIRE)--May 27, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced |
| 2026-05-13 |
AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer
Pivotal U.S. Data Show Sustained Oncologic Control and Safety Profile at 24 months Results Presented at AUA 2026 LATHAM, N.Y. --(BUSINESS WIRE)--May 13, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, |
| 2026-04-02 |
AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued Profitability
Med Tech segment delivered its sixth consecutive quarter of double-digit growth Strong adjusted EBITDA Third consecutive quarter the Company raised full year FY 2026 guidance for net sales and Adjusted EBITDA LATHAM, N.Y. --(BUSINESS WIRE)--Apr. 2, 2026-- AngioDynamics, Inc. |
| 2026-03-31 |
AngioDynamics to Present at the 25th Annual Needham Virtual Healthcare Conference
LATHAM, N.Y. --(BUSINESS WIRE)--Mar. 31, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today |
Past events
| Date | Event | Type |
|---|---|---|
| 2026-08-11 | Canaccord Genuity's 46th Annual Growth Conference | Conference |
| 2026-08-10 | 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference | Conference |
| 2026-07-14 | AngioDynamics’ Fiscal 2026 Fourth Quarter Financial Results | Results publication |
| 2026-06-10 | Goldman Sachs 47th Annual Global Healthcare Conference | Conference |
| 2026-04-14 | 25th Annual Needham Virtual Healthcare Conference | Conference |
| 2026-04-02 | AngioDynamics Fiscal Year 2026 Third Quarter Financial Results | Results publication |
| 2026-03-09 | 2026 Leerink Global Healthcare Conference | Conference |
| 2026-01-14 | 44th Annual J.P. Morgan Healthcare Conference | Conference |
| 2026-01-06 | AngioDynamics Fiscal Year 2026 Second Quarter Financial Results | Results publication |
| 2025-11-10 | UBS Global Healthcare Conference | Conference |